Direct oral anticoagulants and antiplatelet agents. Clinical relevance and options for laboratory testing

Area of Science:

• Pharmacology and Clinical Medicine
• Cardiovascular Disease Management
• Laboratory Diagnostics

Background:

• Oral anticoagulants and platelet receptor blockers are vital for preventing thrombotic complications in cardiovascular disease patients.
• Effective antithrombotic action necessitates regular monitoring through various laboratory assays.
• Novel agents like direct oral anticoagulants (DOACs) and P2Y12 inhibitors have increased the need for specialized testing.

Purpose of the Study:

• To review important and commonly used laboratory assays for monitoring oral anticoagulants and antiplatelet agents.
• To discuss the clinical implications of these assays, particularly for DOACs and P2Y12 receptor blockers.
• To provide an overview of pharmacokinetic and pharmacodynamic assays in current clinical practice.

Main Methods:

• Summary of existing literature on laboratory assays for antithrombotic and antiplatelet agents.
• Classification of assays into pharmacokinetic and pharmacodynamic categories.
• Focus on assays relevant to direct oral anticoagulants (dabigatran, rivaroxaban, apixaban) and P2Y12 inhibitors (prasugrel, ticagrelor).

Main Results:

• Laboratory assays are stratified into pharmacokinetic and pharmacodynamic types.
• DOACs and novel P2Y12 inhibitors have driven the adoption of specific monitoring assays.
• The review highlights the clinical utility and application of these assays in managing cardiovascular patients.

Conclusions:

• Laboratory testing plays a critical role in ensuring the efficacy and safety of oral anticoagulants and antiplatelet therapies.
• The advent of DOACs and new P2Y12 inhibitors necessitates a thorough understanding of available monitoring assays.
• Accurate monitoring supports optimal patient outcomes in the context of cardiovascular disease management.